3 Stocks Under $10 That Fail Our Skeptic's Smell Test

Cheap-looking under-$10 stocks can still be expensive mistakes

A low share price does not make a stock cheap if the business underneath is weak. Even in the $1 to $10 range, many companies have questionable fundamentals, so a low sticker price can still be an expensive trap.

Cheap looks different from cheap

A stock trading in the $5 to $10 range can look more respectable than a sub-$5 name, but that does not make it a bargain. Below $5, investors are squarely in the SEC's less-than-$5 territory, where stocks are widely viewed as speculative. And even above that line, many of these businesses are speculative. Price alone does not tell you much about product appeal, customer loyalty, or whether the model can survive a rough quarter.

Why the warning matters now

The July rotation away from the broader AI trade may open the door to more low-priced stocks, but it does not make every cheap ticker a good business. That is why the screen is simple: skip companies with soft demand, weak economics, or a tight balance sheet.

That is the setup for Tilly's, E.W. Scripps, and Asana-three under-$10 names that fail the smell test for different reasons.

TLYS, SSP, and ASAN: affordable on price, not on fundamentals

TLYS: soft demand and weak economics

Tilly's sells apparel to a youthful, trend-sensitive customer, but the first thing a retailer needs is steady customer demand. That signal has been weak. Same-store sales lagged over the past two years, which points to a real demand problem rather than a simple styling issue.

The economics do not look much better. Persistent operating margin losses suggest the company is still struggling to turn sales into durable profit. Adjusting merchandise or running more promotions will not fix that if the underlying model keeps leaking money.

Valuation does not help the case either. Tilly's still trades at 43.3x forward EV-to-EBITda. For a retailer dealing with soft sales and margin pressure, that is a rich price.

SSP: slow growth and a balance sheet with little flexibility

E.W. Scripps looks familiar, but the sales trend is muted. It has only managed 1.6% annual revenue growth over the last five years. That is not the kind of growth that usually supports a higher multiple.

The balance sheet leaves less room for error. Scripps is carrying an 8× net-debt-to-EBITDA ratio, which can limit flexibility if ad demand or viewer attention weakens again. Over time, that also raises the risk that lenders become less willing to extend additional capital. For now, this looks more like a slow business with leverage than a clean turnaround.

ASAN: useful software, but limited evidence of winning

Asana clearly has a real product, but the growth data still look modest. ARR growth averaged 9.6% over the last year. That is positive, but in work-management software it does not yet signal clear market acceleration.

Stickiness is the bigger question. net revenue retention rate of 96% demonstrates high turnover, which matters in a category where switching costs can be low. Combined with a drawn-out sales process and integration hurdles with enterprise clients, the picture is one of a useful tool that still has to work hard to grow and retain customers.

What would improve the setup

This is not a claim that these companies have no future. It is a reminder not to pay for recovery before the operating signals improve.

Until those signals show up, these remain stocks we would still avoid.

A better checklist for hunting stocks under $10

If you want a better setup in low-priced stocks, start with a checklist rather than a headline.

A practical place to begin is with stocks priced under $10 that also carry a Zacks Rank less than or equal to 2 and show at least 25% fair-value upside. That does not guarantee a winner, but it can help filter out the easiest mistakes: buying a stock just because the share price is low, or overpaying for a business without support from expectations or valuation.

What to look for instead

• Demand: Are customers coming back on their own, or is management leaning heavily on promotions or pitch decks?
• Economics: Can the company hold more of each dollar of sales over time without constant financial engineering?
• Durability: Does the business have enough balance-sheet room to handle a rough quarter without stretching?

Rotation alone is not enough. The better under-$10 opportunities are the ones that still look reasonable when the market narrative fades.